Anzeige
Mehr »
Dienstag, 20.01.2026 - Börsentäglich über 12.000 News
98,7% Goldausbeute ohne Cyanid - kommt jetzt der Milliarden-Deal?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

IBEX MEDIUM CAP 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im IBEX MEDIUM CAP

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
12:30Neinor announces 2025 results: €700 million revenue, €110 million EBITDA, approximately 2,900 units delivered-
12:24Neinor Homes completes a transformational year, delivering on its FY25 guidance and positioning for further growth1
10:31DIA plans to create around 1,200 new jobs in Spain in 20262
08:37NEINOR HOMES, S.A.: FY25 preliminary results2
MoVIDRALA, S.A.: VIDRALA reports the transactions carried out under its share buy-back programme between 12 and 16 January 2026.2
MoGRENERGY RENOVABLES, S.A.: Liquidity contract 4Q251
FrHBX Group Plans Share Buyback And Regular Dividends3
FrMobility minister: Spanish firm CAF willing to collaborate with Alstom on SNCB trains18
FrHBX GROUP INTERNATIONAL PLC: HBX Group 2026 AGM notice3
FrMelia feiert Debüt auf den Malediven1
FrCAF to manufacture 10 additional regional trains for French operator SNCF Voyageurs for €80 million1
DoDia Invests €180m In Promotions To Boost Customer Savings1
DoRenommierte Auszeichnung: Almirall erneut als Top Employer in Deutschland ausgezeichnet225Hamburg/Reinbek (ots) - - Das Top Employers Institute zertifiziert weltweit Unternehmen, die hohe Standards in Personalentwicklung und Arbeitskultur erfüllen.- Almirall, ein globales biopharmazeutisches...
► Artikel lesen
DoAlmirall, S.A.: Almirall Announces "LumiNE", a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema334 Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab...
► Artikel lesen
MiGrenergy secures capacity contracts for 2.1GWh storage projects in Poland-
MiAlmirall, S.A.: Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference358 Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies*...
► Artikel lesen
13.01.Grenergy wins 2.1GWh Polish storage awards2
13.01.HBX GROUP INTERNATIONAL PLC: HBX GROUP Announces Q1 2026 trading update10